X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (668) 668
index medicus (556) 556
diabetes mellitus, type 2 - drug therapy (437) 437
male (331) 331
pharmacology & pharmacy (331) 331
animals (311) 311
type 2 diabetes (293) 293
dipeptidyl-peptidase iv inhibitors - therapeutic use (287) 287
glucagon-like peptide-1 (248) 248
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (247) 247
hypoglycemic agents - therapeutic use (235) 235
pharmacokinetics (219) 219
dipeptidyl-peptidase iv inhibitors - pharmacology (212) 212
female (200) 200
diabetes (180) 180
double-blind (180) 180
sitagliptin (180) 180
dipeptidyl-peptidase iv inhibitors - adverse effects (172) 172
middle aged (167) 167
adult (160) 160
dipeptidyl peptidase 4 - metabolism (160) 160
hypoglycemic agents - pharmacokinetics (159) 159
rats (158) 158
endocrinology & metabolism (156) 156
dipeptidyl peptidase-4 inhibitor (153) 153
dipeptidyl-peptidase iv inhibitors - administration & dosage (153) 153
adamantane - analogs & derivatives (150) 150
hypoglycemic agents - pharmacology (137) 137
glycemic control (129) 129
hypoglycemic agents - adverse effects (129) 129
vildagliptin (128) 128
sitagliptin phosphate (121) 121
linagliptin (120) 120
glucose (118) 118
hypoglycemic agents - administration & dosage (114) 114
metformin (112) 112
dpp-4 inhibitor (111) 111
treatment outcome (110) 110
administration, oral (107) 107
drug therapy, combination (106) 106
aged (104) 104
diabetes mellitus, type 2 - blood (103) 103
hypoglycemic agents (102) 102
research (100) 100
safety (100) 100
chemistry, medicinal (98) 98
mice (98) 98
blood glucose - drug effects (97) 97
dose-response relationship, drug (96) 96
type-2 diabetes-mellitus (96) 96
blood glucose - metabolism (94) 94
drug therapy (91) 91
dipeptidyl-peptidase iv inhibitors (89) 89
insulin (89) 89
pharmacodynamics (89) 89
diabetes mellitus (88) 88
efficacy (87) 87
beta-cell function (86) 86
type 2 diabetes mellitus (86) 86
area under curve (80) 80
dipeptidyl-peptidase-iv (78) 78
adamantane - pharmacokinetics (77) 77
improves glycemic control (77) 77
internal medicine (73) 73
care and treatment (72) 72
double-blind method (72) 72
glp-1 (72) 72
iv inhibitor (72) 72
drug interactions (71) 71
diabetes mellitus, type 2 - metabolism (70) 70
glucagon (69) 69
dipeptidyl-peptidase iv inhibitors - chemistry (68) 68
dosage and administration (68) 68
adamantane - therapeutic use (67) 67
analysis (67) 67
structure-activity relationship (66) 66
cross-over studies (65) 65
peptidase (64) 64
pyrrolidines - pharmacokinetics (64) 64
dipeptidyl peptidase-4 inhibitors (63) 63
young adult (62) 62
incretin (61) 61
saxagliptin (61) 61
therapy (59) 59
dipeptidyl peptidase 4 (57) 57
nitriles - pharmacokinetics (56) 56
dpp-4 inhibitors (55) 55
pyrazines - therapeutic use (55) 55
triazoles - therapeutic use (55) 55
health aspects (54) 54
metformin - therapeutic use (54) 54
review (54) 54
diabetes therapy (53) 53
glycated hemoglobin a - metabolism (53) 53
dipeptidyl peptidase-iv (52) 52
pyrrolidines - pharmacology (51) 51
adamantane - adverse effects (50) 50
biochemistry & molecular biology (50) 50
pharmacology/toxicology (50) 50
adamantane - pharmacology (49) 49
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (820) 820
German (4) 4
Chinese (3) 3
French (3) 3
Japanese (3) 3
Danish (2) 2
Korean (2) 2
Hungarian (1) 1
Italian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2010, Volume 12, Issue 8, pp. 648 - 658
Type 2 diabetes (T2DM) is a complex disease combining defects in insulin secretion and insulin action. New compounds have been developed for improving... 
DPP‐4 inhibitor | linagliptin | sitagliptin | vildagliptin | alogliptin | pharmacokinetics | type 2 diabetes mellitus | saxagliptin | DPP-4 inhibitor | Alogliptin | Sitagliptin | Linagliptin | Vildagliptin | Type 2 diabetes mellitus | Pharmacokinetics | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | RECEPTOR AGONISTS | SINGLE-DOSE PHARMACOKINETICS | RENAL IMPAIRMENT | ORAL ANTIDIABETIC AGENTS | HEALTHY MALE-VOLUNTEERS | IV INHIBITOR | ENDOCRINOLOGY & METABOLISM | HEPATIC IMPAIRMENT | TYPE-2 DIABETES-MELLITUS | Dipeptides - pharmacokinetics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Half-Life | Male | Pyrazines - therapeutic use | Nitriles - pharmacokinetics | Pyrrolidines - therapeutic use | Drug Interactions | Adamantane - therapeutic use | Female | Triazoles - pharmacokinetics | Sitagliptin Phosphate | Adamantane - pharmacokinetics | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Dipeptides - therapeutic use | Pyrrolidines - pharmacokinetics | Randomized Controlled Trials as Topic | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Pyrazines - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Type 2 diabetes | Physiological aspects | Glucose | Metabolites | Dextrose | Cytochrome P-450
Journal Article
Journal Article
Kidney International, ISSN 0085-2538, 02/2015, Volume 87, Issue 2, pp. 308 - 322
This review mainly focuses on metformin, and considers oral antidiabetic therapy in kidney transplant patients and the potential benefits and risks of... 
Type 2 diabetes | lactic acidosis | pharmacokinetics | metformin | chronic kidney disease | antidiabetic agents | ORGANIC CATION TRANSPORTER-1 | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | OXYGEN-CONSUMPTION | INDUCED HYPOGLYCEMIA | CLINICAL PHARMACOKINETICS | IN-VITRO DEGRADATION | UROLOGY & NEPHROLOGY | MITOCHONDRIAL DYSFUNCTION | LACTIC-ACIDOSIS | CHRONIC KIDNEY-DISEASE | TYPE-2 DIABETES-MELLITUS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Diabetic Nephropathies - drug therapy | Glycoside Hydrolase Inhibitors - therapeutic use | Incretins - pharmacokinetics | Diabetes Mellitus, Type 2 - metabolism | Metformin - adverse effects | Thiazolidinediones - pharmacokinetics | Thiazolidinediones - therapeutic use | Glycoside Hydrolase Inhibitors - pharmacokinetics | Acidosis, Lactic - etiology | Renal Insufficiency - drug therapy | Sulfonylurea Compounds - pharmacokinetics | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Metformin - pharmacokinetics | Diabetic Nephropathies - metabolism | Sulfonylurea Compounds - therapeutic use | Renal Insufficiency - metabolism | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Acidosis, Lactic - metabolism | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - pharmacokinetics | Insulin - therapeutic use | Kidney Transplantation - adverse effects
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 04/2014, Volume 57, Issue 8, pp. 3205 - 3212
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2016, Volume 18, Issue 4, pp. 333 - 347
Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent does not generally provide durable glycaemic control over the long... 
linagliptin | glyburide | incretin | saxagliptin | diabetes mellitus | omarigliptin | anagliptin | gliclazide | glimepiride | sitagliptin | vildagliptin | gemigliptin | alogliptin | antidiabetic drug | glipizide | glycaemic control | trelagliptin | GLP‐1 | glibenclamide | evogliptin | teneligliptin | Glimepiride | Incretin | GLP-1 | Trelagliptin | Diabetes mellitus | Sitagliptin | Glipizide | Evogliptin | Anagliptin | Glyburide | Antidiabetic drug | Omarigliptin | Gliclazide | Alogliptin | Linagliptin | Vildagliptin | Gemigliptin | Glibenclamide | Glycaemic control | Teneligliptin | Saxagliptin | SEVERE HYPOGLYCEMIA | IV INHIBITOR | ENDOCRINOLOGY & METABOLISM | TYPE-2 DIABETES-MELLITUS | INSULIN SECRETAGOGUES | GLYCEMIC CONTROL | CARDIOVASCULAR EVENTS | DPP-4 INHIBITOR | DOUBLE-BLIND | METFORMIN THERAPY | SAVOR-TIMI 53 | Glycated Hemoglobin A - analysis | Hypoglycemia - epidemiology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Risk | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Weight Gain - drug effects | Sulfonylurea Compounds - administration & dosage | Diabetic Angiopathies - prevention & control | Sulfonylurea Compounds - pharmacokinetics | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Sulfonylurea Compounds - therapeutic use | Sulfonylurea Compounds - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Diabetes Mellitus, Type 2 - blood | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Diabetic Cardiomyopathies - epidemiology | Diabetic Angiopathies - epidemiology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Prescription drugs | Insulin | Side effects | Peptidase | Clinical trials | Metformin | Hypoglycemia | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Patients
Journal Article
Journal Article
10.